BOLD

Boundless Bio Inc

2.62

Oct 02 • 3:59 PM ET +0.03 (1.16%)

2.62

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: LITS NNVC ABVC ALGS DARE EVAX TVRD GRCE INMB VERU

| Held by: VTI VXF IWC

Index	-
Market Cap	59.60M
Enterprise Value	-13.03M
Income	-64.01M
Sales	0.00M
Book/sh	2.94
Cash/sh	3.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Mar 28, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.89
P/C	0.82
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.48
Current Ratio	9.48
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.86
EPS next Y	-0.98
EPS next Q	-0.56
EPS this Y	2.69%
EPS next Y	61.26%
EPS next 5Y	-
EPS past 3/5Y	-8.04% -23.10%
Sales past 3/5Y	- -
EPS Y/Y TTM	1.11%
Sales Y/Y TTM	-
EPS Q/Q	-50.51%
Sales Q/Q	-
Earnings	Aug 17
EPS/Sales Surpr.	0.00% -

Insider Own	23.06%
Insider Trans	5.53%
Inst Own	56.65%
Inst Trans	-2.95%
ROA	-50.56%
ROE	-67.86%
ROIC	-97.02%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-4.54%
SMA50	-5.12%
SMA200	46.43%
Trades

Shs Outstand	22.48M
Shs Float	17.50M
Short Float	4.64%
Short Ratio	4.38
Short Interest	0.81M
52W High	3.16 -17.18%
52W Low	0.96 172.58%
Volatility	5.69% 3.73%
ATR (14)	0.12
RSI (14)	41.85
Beta	0.45
Rel Volume	0.84
Avg Volume	185.25K
Volume	156,529

Perf Week	-1.50%
Perf Month	-9.34%
Perf Quarter	4.80%
Perf Half Y	142.59%
Perf YTD	118.33%
Perf Year	116.53%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	3.00
Target Price	4.00
Prev Close	2.59
Price	2.62
Change %	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Initiated	H.C. Wainwright	Buy	$5
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

Jun-25-26 01:53PM	Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-23-26 10:53PM	Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today (Stocktwits) +85.71%
01:32PM	BOLD Stock Is Up 90% Here's What's Behind The Biggest Rally In Company History (Stocktwits)
07:30AM	Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement (GlobeNewswire)
May-08-26 07:00AM	Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) -5.88%
04:49PM	Loading…
Apr-17-26 04:49PM	Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting (GlobeNewswire)
Mar-17-26 04:52PM	Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 (GlobeNewswire)
Mar-09-26 07:00AM	Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
Mar-04-26 07:00AM	Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-13-26 12:00PM	Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why (Zacks)
Feb-05-26 07:00AM	Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-20-26 07:00AM	Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway (GlobeNewswire)
Nov-24-25 07:00AM	Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Oct-13-25 04:05PM	Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
07:00AM	Loading…
Aug-05-25 07:00AM	Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Jun-05-25 04:58PM	Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-23-25 04:01PM	Boundless Bio Announces Portfolio Prioritization and Runway Extension (GlobeNewswire) -15.58%
May-14-25 12:00PM	Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know (Zacks)
May-09-25 07:00AM	Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 08:23AM	New Strong Sell Stocks for May 1st (Zacks) -8.52%
Apr-03-25 07:00AM	Boundless Bio to Participate in the Needham Virtual Healthcare Conference (GlobeNewswire) -7.38%
Mar-27-25 07:00AM	Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Feb-26-25 07:00AM	Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-03-25 10:00AM	Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-12-24 04:01PM	Boundless Bio Announces Pipeline and Leadership Updates (GlobeNewswire) -12.72% -16.61%
Nov-25-24 07:00AM	Boundless Bio to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire) +8.94%
Nov-07-24 04:01PM	Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +5.42%
Nov-05-24 07:00AM	Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference (GlobeNewswire)
Oct-14-24 08:00AM	Boundless Bio Announces Departure of Chief Financial Officer (GlobeNewswire)
07:00AM	Loading…
Sep-11-24 07:00AM	Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-24 04:28AM	Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO (FierceBiotech.com)
03:32AM	Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? (Insider Monkey)
Aug-12-24 10:53PM	BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 (InvestorPlace) -6.19%
04:01PM	Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-05-24 07:00AM	Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in La Jolla, CA.

MBAZachary D. Hornby

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TANG KEVIN	10% Owner	Aug 26 '26	Sale	2.97	18,300	54,351	2,840,635	Aug 28 04:16 PM
TANG KEVIN	10% Owner	Jul 21 '26	Buy	2.44	2,975	7,259	2,858,935	Jul 21 07:38 PM
TANG KEVIN	10% Owner	Jul 20 '26	Buy	2.44	1,623	3,960	2,855,960	Jul 21 07:38 PM
TANG KEVIN	10% Owner	Jul 17 '26	Buy	2.44	265	647	2,854,337	Jul 21 07:38 PM
TANG KEVIN	10% Owner	Jul 14 '26	Buy	2.43	43,878	106,624	2,833,981	Jul 16 08:10 PM
TANG KEVIN	10% Owner	Jul 16 '26	Buy	2.44	18,491	45,118	2,854,072	Jul 16 08:10 PM
TANG KEVIN	10% Owner	Jul 15 '26	Buy	2.44	1,600	3,904	2,835,581	Jul 16 08:10 PM
TANG KEVIN	10% Owner	Jul 13 '26	Buy	2.42	48,211	116,671	2,790,103	Jul 13 07:06 PM
TANG KEVIN	10% Owner	Jul 10 '26	Buy	2.43	43,367	105,382	2,741,892	Jul 13 07:06 PM
TANG KEVIN	10% Owner	Jul 09 '26	Buy	2.48	7	17	2,698,525	Jul 13 07:06 PM
TANG KEVIN	10% Owner	Jul 06 '26	Buy	2.49	27,062	67,384	2,668,370	Jul 08 08:06 PM
TANG KEVIN	10% Owner	Jul 07 '26	Buy	2.48	15,810	39,209	2,684,180	Jul 08 08:06 PM
TANG KEVIN	10% Owner	Jul 08 '26	Buy	2.46	14,338	35,271	2,698,518	Jul 08 08:06 PM
CRANDELL KEITH	10% Owner	Jul 01 '26	Option Exercise	1.03	16,000	16,480	16,000	Jul 06 05:44 PM
CRANDELL KEITH	10% Owner	Jul 01 '26	Sale	2.49	16,000	39,840	0	Jul 06 05:44 PM
ARCH Venture Fund IX, L.P.	10% Owner	Jul 01 '26	Option Exercise	1.03	16,000	16,480	16,000	Jul 06 05:43 PM
ARCH Venture Fund IX, L.P.	10% Owner	Jul 01 '26	Sale	2.49	16,000	39,840	0	Jul 06 05:43 PM
TANG KEVIN	10% Owner	Jul 01 '26	Buy	2.49	71,612	178,314	2,631,487	Jul 02 07:45 PM
TANG KEVIN	10% Owner	Jun 30 '26	Buy	2.54	26,030	66,112	2,559,875	Jul 02 07:45 PM
TANG KEVIN	10% Owner	Jul 02 '26	Buy	2.49	9,821	24,454	2,641,308	Jul 02 07:45 PM

Open in Screener

FULC

Fulcrum Therapeutics Inc

3.69

Oct 02 • 3:59 PM ET +0.01 (0.27%)

3.69

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

FULC Fulcrum Therapeutics Inc daily Stock Chart

Peers: INCY BMRN KRYS KYMR RYTM CRNX AXSM MDGL VKTX NBIX

| Held by: VTI IWM IWN VXF IBB FESM VTWO SCHA IWC DFMC

Index	RUT
Market Cap	281.54M
Enterprise Value	-32.02M
Income	-85.00M
Sales	0.00M
Book/sh	4.07
Cash/sh	4.18
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.91
P/C	0.88
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	31.35
Current Ratio	31.35
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.21
EPS next Y	-0.12
EPS next Q	-0.07
EPS this Y	48.94%
EPS next Y	79.78%
EPS next 5Y	63.32%
EPS past 3/5Y	21.49% 15.80%
Sales past 3/5Y	- -
EPS Y/Y TTM	0.04%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-24.16%
Sales Q/Q	-
Earnings	Aug 05
EPS/Sales Surpr.	-33.07% -

Insider Own	3.37%
Insider Trans	18.40%
Inst Own	102.88%
Inst Trans	-8.60%
ROA	-30.75%
ROE	-32.38%
ROIC	-27.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.21%
SMA50	-2.44%
SMA200	-44.19%
Trades

Shs Outstand	76.29M
Shs Float	73.73M
Short Float	9.76%
Short Ratio	4.51
Short Interest	7.19M
52W High	15.74 -76.56%
52W Low	2.83 30.39%
Volatility	2.04% 1.71%
ATR (14)	0.08
RSI (14)	37.56
Beta	2.83
Rel Volume	0.97
Avg Volume	1.60M
Volume	1,540,441

Perf Week	-1.34%
Perf Month	-4.16%
Perf Quarter	-0.81%
Perf Half Y	-54.10%
Perf YTD	-67.37%
Perf Year	-61.20%
Perf 3Y	-9.78%
Perf 5Y	-87.01%
Perf 10Y	-
Recom	4.00
Target Price	4.00
Prev Close	3.68
Price	3.69
Change %	0.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-26	Downgrade	JP Morgan	Overweight → Underweight
Jun-02-26	Downgrade	Truist	Buy → Hold	$4
Jun-02-26	Downgrade	Stifel	Buy → Hold	$3
Jun-02-26	Downgrade	Piper Sandler	Overweight → Neutral	$3
Jun-02-26	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Jun-02-26	Downgrade	H.C. Wainwright	Buy → Neutral	$3
Jan-12-26	Initiated	JP Morgan	Overweight	$20
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy	$4 → $12
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$10
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral	$17 → $4
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15 → $4
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform	$10 → $2
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral	$5 → $10
May-20-24	Initiated	Cantor Fitzgerald	Overweight	$23
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14

Show Previous Ratings

Sep-30-26 09:10AM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and its Board for Possible Securities Law Violations (Newsfile)
Sep-25-26 07:39AM	Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-18-26 12:55PM	Are FULC, WEAV, BWIN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-15-26 11:27AM	Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-14-26 05:20PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Investors Who Suffered Losses (Newsfile)
06:10PM	Loading…
Sep-10-26 06:10PM	Kaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the Firm (Newsfile)
Sep-09-26 03:24PM	Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? (PR Newswire)
Sep-04-26 02:40PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Shareholders for Possible Securities Law Violations (Newsfile)
Sep-02-26 10:40AM	Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-28-26 01:50PM	Are UTZ, VCTR, FULC, CZR Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-27-26 05:49PM	Slate Medicines Starts Migraine Treatment Study (Exec Edge)
Aug-24-26 08:37AM	Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? (PR Newswire)
Aug-19-26 11:30AM	Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) to Contact the Firm to Learn About Their Legal Rights (Newsfile)
Aug-18-26 04:56AM	Fulcrum and Slate Medicines sign merger agreement (Hospital Management)
Aug-17-26 10:10PM	Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? (PR Newswire)
12:11PM	Loading…
12:11PM	Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies (Exec Edge)
11:15AM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) for Potential Violations of the Federal Securities Laws (Newsfile)
07:00AM	Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies (GlobeNewswire)
06:23AM	Slate, Fulcrum to combine in reverse merger (BioPharma Dive)
Aug-14-26 02:00PM	Kaplan Fox & Kilsheimer LLP is Investigating Fulcrum Therapeutics, Inc. (FULC) for Possible Securities Law Violations (Newsfile)
Aug-12-26 01:30PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) on Behalf of Investors for Potential Securities Law Violations (Newsfile)
Aug-10-26 12:32PM	Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (FULC) and Encourages Investors Who Suffered Losses to Contact the Firm (Newsfile)
Aug-05-26 12:00PM	Kaplan Fox Urges Fulcrum Therapeutics, Inc. (FULC) Investors to Contact the Firm About Possible Securities Law Violations (Newsfile)
Jun-02-26 11:04PM	Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -51.09%
09:43AM	Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls (The Fly)
08:08AM	Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug (BioPharma Dive)
07:53AM	This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has 'No Viable Path Forward.' (Barrons.com)
Jun-01-26 05:50PM	FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk (Stocktwits) -7.23%
04:05PM	Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review (GlobeNewswire)
May-08-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:02AM	Loading…
Apr-28-26 03:02AM	Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Apr-27-26 12:46PM	Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
11:08AM	Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations (InvestorsHub)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 (GlobeNewswire)
06:55AM	Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors (GlobeNewswire)
Apr-20-26 08:00AM	Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET (GlobeNewswire)
Mar-19-26 08:00AM	MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease (GlobeNewswire)
Mar-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-03-26 08:30AM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-25-26 10:27AM	Fulcrum Therapeutics move lower overdone, says Stifel (TipRanks)
Feb-24-26 08:05PM	Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) -21.21%
11:47AM	Fulcrum Therapeutics Q4 Earnings Call Highlights (MarketBeat)
09:48AM	What's Going On With Fulcrum Therapeutics Stock Tuesday? (Benzinga)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-17-26 08:00AM	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-12-26 09:55AM	Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
Feb-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Jan-09-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 08:00AM	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-25 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet (Zacks) -5.42%
Dec-21-25 07:31AM	Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study (Insider Monkey)
Dec-10-25 07:48AM	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.48%
Dec-08-25 04:01PM	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock (GlobeNewswire) +45.96% +12.39%
Dec-06-25 05:30PM	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-05-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +45.96%
Dec-02-25 08:30AM	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 (GlobeNewswire) -9.32%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
Nov-19-25 04:20PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) +18.29%
Nov-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:45PM	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire) -7.21%
Oct-29-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 (GlobeNewswire) -6.40%
Oct-22-25 08:54AM	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET (GlobeNewswire) -6.80%
Oct-14-25 07:00AM	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Oct-10-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Sep-12-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 08:00AM	Fulcrum Therapeutics to Present at Upcoming Investor Meetings (GlobeNewswire)
Aug-08-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:48AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 (GlobeNewswire)
06:45AM	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-28-25 04:01PM	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 01:17AM	Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory (Insider Monkey)
May-29-25 04:10PM	Fulcrum Therapeutics to Present at Upcoming Medical Meetings (GlobeNewswire)
08:30AM	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-09-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77%
May-08-25 04:05PM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire) +6.71%
May-02-25 03:03AM	Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... (GuruFocus.com) +28.31%
01:27AM	Q1 2025 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 01:55PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +13.77%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 (GlobeNewswire)
Apr-24-25 08:00AM	Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET (GlobeNewswire)
Apr-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.55%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-04-25 04:05PM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-25 02:04AM	Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.27%
01:28AM	Q4 2024 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 (GlobeNewswire)
01:52AM	Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result (GuruFocus.com)
Feb-18-25 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:05PM	Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-28-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why (Zacks)
Nov-26-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) +11.27%
Nov-14-24 02:07AM	Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... (GuruFocus.com) -6.74%
Nov-13-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 08:00AM	Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET (GlobeNewswire)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

CEOMr. Alexander C. Sapir

CPAMr. Alan A. Musso C.M.A.

Chief Legal OfficerMr. Curtis G. Oltmans J.D.

Ph.D.Dr. Bradley E. Bernstein M.D.

FounderDr. Michael R. Green

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Greg Tourangeau	former officer	Sep 02 '26	Proposed Sale	3.87	14,062	54,420		Sep 02 09:30 AM
TANG KEVIN	10% Owner	Jul 16 '26	Buy	3.56	116,671	415,349	7,030,000	Jul 20 09:10 PM
TANG KEVIN	10% Owner	Jul 17 '26	Buy	3.52	50,945	179,326	7,080,945	Jul 20 09:10 PM
TANG KEVIN	10% Owner	Jul 14 '26	Buy	3.57	129,603	462,906	6,805,952	Jul 15 07:50 PM
TANG KEVIN	10% Owner	Jul 15 '26	Buy	3.56	107,377	382,262	6,913,329	Jul 15 07:50 PM
TANG KEVIN	10% Owner	Jul 13 '26	Buy	3.54	12,966	45,900	6,676,349	Jul 15 07:50 PM
Ezekowitz Alan	Director	Jun 26 '26	Sale	3.65	18,000	65,614	10,927	Jun 30 04:30 PM
ALAN EZEKOWITZ	Director	Jun 26 '26	Proposed Sale	3.61	18,000	64,980		Jun 26 04:26 PM
Gould Robert J	Director	Feb 02 '26	Sale	10.72	15,000	160,857	454,864	Feb 04 04:10 PM
Gould Robert J	Director	Jan 02 '26	Sale	11.87	15,000	178,089	469,864	Jan 06 04:30 PM
Oltmans Curtis Gale	Chief Legal Officer	Dec 15 '25	Sale	12.92	3,452	44,600	10,252	Dec 17 04:10 PM
CURTIS G OLTMANS	Officer	Dec 15 '25	Proposed Sale	13.00	3,452	44,876		Dec 15 04:32 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Dec 08 '25	Sale	13.98	4,175,139	58,377,021	6,053,960	Dec 10 04:42 PM
RA Capital Healthcare Fund LP	10% Owner	Dec 08 '25	Proposed Sale	12.99	4,175,139	54,235,056		Dec 08 05:40 PM
Gould Robert J	Director	Nov 19 '25	Sale	11.03	15,000	165,495	484,864	Nov 21 04:15 PM
ROBERT J GOULD	Director	Nov 19 '25	Proposed Sale	9.73	45,000	437,850		Nov 19 04:20 PM

Open in Screener

AUPH

Aurinia Pharmaceuticals Inc

15.83

Oct 02 • 3:59 PM ET -0.12 (-0.75%)

15.83

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology Canada Mid NASD

AUPH Aurinia Pharmaceuticals Inc daily Stock Chart

Peers: PHVS MIRM PTCT RYTM BMRN KRYS VKTX AXSM INCY NBIX

| Held by: IWM IWO IBB VTWO FESM VHT PSC AVSC VTWG SPDW

Index	RUT
Market Cap	2.11B
Enterprise Value	1.73B
Income	314.11M
Sales	311.51M
Book/sh	4.63
Cash/sh	3.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	128
IPO	Oct 20, 2003

P/E	6.92
Forward P/E	13.44
PEG	-
P/S	6.76
P/B	3.42
P/C	4.75
P/FCF	12.09
EV/EBITDA	10.79
EV/Sales	5.54
Quick Ratio	4.97
Current Ratio	5.42
Debt/Eq	0.10
LT Debt/Eq	0.07
Option/Short	Yes / Yes

EPS (ttm)	2.29
EPS next Y	1.18
EPS next Q	0.22
EPS this Y	-54.40%
EPS next Y	24.79%
EPS next 5Y	-11.46%
EPS past 3/5Y	- -
Sales past 3/5Y	28.30% 41.38%
EPS Y/Y TTM	444.46%
Sales Y/Y TTM	19.76%
EPS Q/Q	79.16%
Sales Q/Q	18.87%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	16.67% 3.45%

Insider Own	11.21%
Insider Trans	5.53%
Inst Own	58.32%
Inst Trans	3.45%
ROA	48.52%
ROE	66.12%
ROIC	47.53%
Gross Margin	90.36%
Oper. Margin	45.15%
Profit Margin	100.84%
SMA20	-3.36%
SMA50	-1.02%
SMA200	1.76%
Trades

Shs Outstand	132.91M
Shs Float	118.13M
Short Float	7.26%
Short Ratio	7.91
Short Interest	8.58M
52W High	19.25 -17.77%
52W Low	10.90 45.21%
Volatility	1.97% 2.45%
ATR (14)	0.42
RSI (14)	41.36
Beta	1.41
Rel Volume	0.75
Avg Volume	1.08M
Volume	813,425

Perf Week	-3.71%
Perf Month	-2.82%
Perf Quarter	2.19%
Perf Half Y	1.41%
Perf YTD	-0.75%
Perf Year	40.59%
Perf 3Y	112.77%
Perf 5Y	-27.42%
Perf 10Y	425.91%
Recom	1.67
Target Price	18.00
Prev Close	15.95
Price	15.83
Change %	-0.75%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$16
Nov-07-25	Upgrade	Jefferies	Hold → Buy	$21
Nov-05-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15
Jul-30-25	Resumed	H.C. Wainwright	Buy	$17
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight	$34 → $25
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform	$33 → $31
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform	$32
Jan-25-21	Reiterated	H.C. Wainwright	Buy	$30 → $35
Nov-03-20	Reiterated	H.C. Wainwright	Buy	$34 → $28
Jun-17-20	Initiated	BTIG Research	Buy	$20
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy	$27
Dec-16-19	Reiterated	H.C. Wainwright	Buy	$25 → $32
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight	$14 → $16
Feb-08-18	Initiated	RBC Capital Mkts	Outperform	$9
Oct-30-17	Reiterated	H.C. Wainwright	Buy	$10 → $12
May-18-17	Reiterated	H.C. Wainwright	Buy	$12 → $10
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight	$14
Mar-22-17	Reiterated	FBR & Co.	Outperform	$9 → $11

Show Previous Ratings

Sep-04-26 06:59PM	Immatics and 4 More Stocks See Action From Activist Investors (Barrons.com)
Aug-19-26 06:15PM	AUPH Stock Rallies 6% After-Hours Heres Why (Stocktwits) +5.69% +6.80%
04:05PM	Aurinia Settles Patent Litigation with Teva (Business Wire)
Aug-06-26 08:11AM	Aurinia: Q2 Earnings Snapshot (Associated Press) +6.19%
08:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress (Business Wire)
08:00AM	Loading…
Jul-06-26 08:00AM	Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis (Business Wire)
Jun-12-26 06:47PM	Aurinia Pharmaceuticals and Four More Stocks See Activist Action (Barrons.com)
Jun-04-26 07:00AM	LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death (Business Wire)
May-19-26 08:30AM	Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences (Newsfile)
May-07-26 08:06AM	Aurinia: Q1 Earnings Snapshot (Associated Press) -6.80%
Mar-30-26 11:00AM	United rises on IPF results; Biogen scores positive lupus data and an approval (BioPharma Dive)
11:00AM	United rises on IPF data; Biogen scores positive lupus data and an approval (BioPharma Dive)
Mar-23-26 12:13PM	Mutiny At Aurinia Pharmaceuticals? Biotech Soars On C-Suite Shake-Up. (Investor's Business Daily)
11:00AM	MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition (Business Wire)
08:00AM	Aurinia Announces Management Transition (Business Wire)
08:29PM	Loading…
Mar-13-26 08:29PM	W.R. Berkley, Ziff Davis, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-26 01:35PM	Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77 (Investor's Business Daily) +6.29%
Mar-01-26 04:27AM	Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 (Insider Monkey)
Feb-26-26 08:03PM	Aurinia Pharmaceuticals Inc. Q4 2025 Earnings Call Summary (Moby)
04:10PM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
04:06PM	Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets (Benzinga)
12:06PM	Aurinia Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
08:15AM	Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates (Zacks)
06:12AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress (Business Wire)
Feb-25-26 12:15PM	United Therapeutics (UTHR) Surpasses Q4 Earnings Estimates (Zacks)
Feb-24-26 01:14PM	CRISPR Therapeutics Stock Sees RS Rating Rise To 73 (Investor's Business Daily)
01:02PM	Xenon Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Feb-19-26 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026 (Business Wire)
Feb-11-26 05:10PM	Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates (Zacks)
02:03PM	Loading…
Feb-06-26 02:03PM	This Pharma Stock With Earnings Seen Soaring 1,854% Forms Bullish Base (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Dec-26-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-10-25 09:40AM	Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year? (Zacks)
Dec-05-25 12:00PM	What Makes Aurinia Pharmaceuticals (AUPH) a Strong Momentum Stock: Buy Now? (Zacks)
Dec-02-25 10:15AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Nov-27-25 09:15AM	Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-24-25 09:40AM	Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-07-25 12:20PM	Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Aurinia Pharmaceuticals Inc (AUPH) Q3 2025 Earnings Call Highlights: Strong Lupkynis Sales and ... (GuruFocus.com) +8.35%
07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
06:11AM	Aurinia: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress (Business Wire)
Nov-03-25 06:00AM	Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025 (Business Wire)
05:00AM	Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark (BioPharma Dive)
04:49AM	Stocks to Watch Monday: Berkshire Hathaway, Onsemi, Palantir (The Wall Street Journal)
Nov-02-25 07:59PM	FDA Official Steps Down, Sued by Drugmaker (The Wall Street Journal)
Oct-16-25 01:40PM	Xencor Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-15-25 06:00AM	Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025 (Business Wire)
Oct-08-25 01:05PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-30-25 12:34PM	Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-29-25 08:27PM	Aurinia Responds to Now Retracted LinkedIn Post (Business Wire) -15.83%
03:19PM	Cytokinetics Stock Scores RS Rating Jump To 83 (Investor's Business Daily)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-08-25 02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Sep-03-25 02:02PM	PTC Therapeutics Stock Sees RS Rating Improve To 77 (Investor's Business Daily)
Aug-27-25 01:57PM	KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82 (Investor's Business Daily)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily)
Aug-07-25 02:00PM	Supernus Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Aug-04-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know (Zacks) +9.15%
Aug-01-25 05:01AM	Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +13.47%
Jul-31-25 07:15AM	Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates (Zacks)
06:13AM	Aurinia: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025 (Business Wire)
Jul-22-25 06:00AM	Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 (Business Wire)
Jul-02-25 08:48AM	Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options (Zacks)
Jun-30-25 06:00AM	Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200) (Business Wire)
Jun-29-25 05:00PM	Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025 (Business Wire)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
May-30-25 08:46AM	Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
May-22-25 06:00AM	New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis (Business Wire)
May-13-25 09:24AM	Company News for May 13, 2025 (Zacks)
03:03AM	Aurinia Pharmaceuticals Inc (AUPH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
06:07AM	Aurinia: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 (Business Wire)
May-05-25 06:00AM	Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025 (Business Wire)
Apr-30-25 06:00AM	Glass Lewis Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-29-25 06:00AM	ISS Recommends That Aurinia Shareholders Vote FOR All Proposals at 2025 Annual General Meeting (Business Wire)
Apr-26-25 10:54AM	Aurinia Pharmaceuticals: Shareholder Pressure And Sales Growth (Seeking Alpha)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 04:05PM	Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting (Business Wire)
09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
Mar-25-25 10:41AM	Aurinia Pharmaceuticals Inc. (AUPH): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-07-25 04:47PM	Signet Jewelers, Big Bear, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-04-25 01:14PM	Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock? (Zacks)
Feb-28-25 02:13AM	Aurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +5.30%
Feb-27-25 07:10AM	Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates (Zacks) -5.03%
06:28AM	Aurinia: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress (Business Wire)
Feb-25-25 12:31PM	Is Aurinia Pharmaceuticals Inc. (AUPH) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-20-25 04:05PM	Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 (Business Wire)
Jan-22-25 12:00PM	Aurinia (AUPH) Upgraded to Buy: Here's Why (Zacks)
Dec-10-24 08:30AM	Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options (Zacks) +14.35%
Nov-18-24 05:53PM	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Business Wire)
Nov-15-24 06:00AM	Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS in Managing LN at American College of Rheumatology Convergence 2024 (Business Wire)

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Chairman & CEOMr. Kevin C. Tang

Chief Legal OfficerMr. Stephen P. Robertson

ConsultantMr. Peter S. Greenleaf M.B.A.

Chief Financial OfficerMr. Michael S. Hearne CPA

Chief Operating OfficerMr. Ryan Cole

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Robertson Stephen P.	Chief Legal Officer	Sep 10 '26	Sale	15.95	11,939	190,427	588,848	Sep 11 04:26 PM
Robertson Stephen P.	Chief Legal Officer	Aug 21 '26	Sale	16.97	20,975	355,946	600,787	Aug 25 09:29 PM
Stephen P. Robertson	Officer	Aug 21 '26	Proposed Sale	15.30	47,000	719,100		Aug 21 08:54 PM
GREGORY KEENAN	Former Affiliate	Jun 05 '26	Proposed Sale	16.52	9,593	158,490		Jun 05 04:27 PM
GREGORY KEENAN	Former Affiliate	Jun 04 '26	Proposed Sale	16.34	25,000	408,435		Jun 04 04:12 PM
TANG KEVIN	Chief Executive Officer	Jun 01 '26	Buy	15.28	343,620	5,250,520	12,838,101	Jun 02 09:54 PM
TANG KEVIN	Chief Executive Officer	May 29 '26	Buy	15.31	264,981	4,056,951	12,494,481	Jun 02 09:54 PM
TANG KEVIN	Chief Executive Officer	Jun 02 '26	Buy	15.28	206,005	3,147,756	13,044,106	Jun 02 09:54 PM
GREGORY KEENAN	Officer	Jun 02 '26	Proposed Sale	15.39	25,000	384,750		Jun 02 04:13 PM
PETER GREENLEAF	Former Affiliate	May 11 '26	Proposed Sale	15.84	3,136,201	49,677,424		May 11 04:11 PM
MATTHEW MAXWELL DONLEY	Former Affiliate	May 11 '26	Proposed Sale	15.84	717,688	11,368,178		May 11 04:10 PM
JOSEPH MILLER	Former Affiliate	May 11 '26	Proposed Sale	15.84	500,503	7,927,968		May 11 04:07 PM
TANG KEVIN	Director	Feb 27 '26	Buy	13.99	516,439	7,226,535	11,845,939	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 02 '26	Buy	14.26	199,353	2,842,833	12,045,292	Mar 03 05:35 PM
TANG KEVIN	Director	Mar 03 '26	Buy	14.22	184,208	2,619,438	12,229,500	Mar 03 05:35 PM

BOLD

Boundless Bio Inc

FULC

Fulcrum Therapeutics Inc

AUPH

Aurinia Pharmaceuticals Inc

Upgrade your Finviz experience